ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 108,66
-1,07%
Dow Jones
39 806,77
0,00%
DAX
18 667,09
-0,53%
Brent Oil
82,565
-1,16%
Bitcoin
71 193,90
-0,36%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alpine Immune Sciences Inc (ALPN)

  7. Alpine Immune Sciences Inc (ALPN) Actualités

ALPN

Alpine Immune Sciences (ALPN)

Alpine Immune Sciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALPN
DateHeureSourceTitreSymboleSociété
21/05/202402h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414h53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414h42Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414h27Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
09/05/202422h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALPNAlpine Immune Sciences Inc
09/05/202422h00Business WireAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202422h27PR Newswire (US)Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202413h24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202422h15Business WireAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA NephropathyNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202422h01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
01/04/202415h00Business WireAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024NASDAQ:ALPNAlpine Immune Sciences Inc
21/03/202412h45Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024NASDAQ:ALPNAlpine Immune Sciences Inc
20/03/202421h30Business WireAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
18/03/202421h05Business WireAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
07/03/202422h30Business WireAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
26/02/202422h30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
14/02/202422h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
21/12/202322h15Business WireAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieNASDAQ:ALPNAlpine Immune Sciences Inc
18/12/202322h30Business WireAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
22/11/202316h25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
20/11/202322h30Business WireAlpine Immune Sciences to Participate in the Evercore ISI HealthconX ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
15/11/202315h00Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
14/11/202322h15Business WireAlpine Immune Sciences Reports Third Quarter 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
13/11/202315h00Business WireAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202303h41Business WireAlpine Immune Sciences Announces Pricing of $150 Million Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202303h37Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ALPNAlpine Immune Sciences Inc
06/11/202312h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALPNAlpine Immune Sciences Inc
06/11/202312h00Business WireAlpine Immune Sciences Announces Proposed Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
03/11/202314h00Business WireAlpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual MeetingNASDAQ:ALPNAlpine Immune Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:ALPN

Dernières Valeurs Consultées

BITV
REEFEUR
Reef.finance
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés